Use your browser's BACK button to return to your page of origin.
The epidemiology of fluoroquinolone-resistant Neisseria gonorrhoeae in Hawaii, 2001.
Clinical Infectious Diseases 2004;38:649-654.
Newman LM, Wang SA, Ohye RG, O'Connor N, Lee MV, Weinstock
HS.
Abstract
Increases in the number of infections with fluoroquinolone-resistant Neisseria
gonorrhoeae in Asia and the United States threaten the efficacy of fluoroquinolones
as inexpensive, single-dose, orally administered treatments for gonorrhea.
This report describes the findings of a field investigation of an increase
in the number of infections with ciprofloxacin-resistant N. gonorrhoeae (CipRGC)
in Hawaii in 2001. We conducted a case review of 53 patients with CipRGC,
who constituted 20% of the 267 patients with cultures positive for N. gonorrhoeae
during this period. Nearly one-half of patients with CipRGC were seen by
clinicians in private practice, one-third were seen by clinicians at a sexually
transmitted diseases (STD) clinic, and only 2% were seen by clinicians in
the military. Among the 117 patients with culture-confirmed gonorrhea who
attended the public STD clinic, we found a prevalence of infection with CipRGC
of 17%. The demographic and clinical characteristics of patients with CipRGC
were similar to those of patients with gonorrhea that was not resistant to
ciprofloxacin, suggesting that fluoroquinolone-resistant gonorrhea has become
endemic in Hawaii.